줄기세포 제조 시장 보고서 : 제품별, 용도별, 최종사용자별, 지역별(2025-2033년)

Stem Cell Manufacturing Market Report by Product, Application, End User, and Region 2025-2033

US $ 2,999 ￦ 4,339,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 3,999 ￦ 5,786,000

PDF & Excel (5 User License)

PDF, Excel 보고서를 동일 사업장의 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,999 ￦ 7,233,000

PDF & Excel (Corporate License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 줄기세포 제조 시장 규모는 2024년에 142억 달러에 달했습니다. IMARC Group은 2025-2033년의 성장률(CAGR)이 6.8%로, 2033년에는 258억 달러에 달할 것으로 예측하고 있습니다. 줄기세포 연구에 대한 투자 증가, 만성질환 유병률 증가, 생명공학 기술 발전, 산학협력, 엄격한 규제, 줄기세포 치료에 대한 인식 확대 등이 시장 성장을 가속하고 있습니다.

줄기세포 제조 시장 분석 :

• 주요 시장 성장 촉진요인: 줄기세포 연구에 대한 벤처캐피털의 투자 확대, 정부의 우호적인 정책이 줄기세포 제조 시장을 크게 견인하고 있습니다. 이는 헬스케어 및 재생의료 발전에서 줄기세포의 잠재력에 대한 인식이 높아진 것을 반영합니다.
• 주요 시장 동향 : 줄기세포 제조 시장의 주요 동향으로는 줄기세포 연구 및 재생의료에 대한 지출 증가, 공정 자동화, 업계 기업 간의 협력 관계 증가, 바이오리액터 기술의 급속한 발전 등이 있습니다.
• 지역적 동향 : 북미는 주요 생명공학 및 제약 기업의 존재, 줄기세포 제조 임상시험 및 상용화를 위한 지원적인 규제 프레임워크, 탄탄한 연구개발(R&D) 인프라, 재생의료 치료에 대한 수요 증가 등 여러 요인으로 인해 줄기세포 제조 시장을 선도하고 있습니다. 시장을 주도하고 있습니다.
• 경쟁 구도: 줄기세포 제조 산업의 주요 시장 기업으로는 Anterogen Co. Ltd., Becton Dickinson and Company, Bio-Rad Laboratories Inc. FUJIFILM Holdings Corporation, Lonza Group AG, Merck KGaA, Sartorius AG, Takara Bio Inc.
• 과제와 기회: 바이오테크놀러지와 바이오의약품 산업을 지원하는 정부 구상은 시장에 큰 기회를 제공합니다. 보조금, 세제 혜택, 보조금과 같은 구상은 연구개발을 촉진하고, 투자를 유치하고, 첨단 기술을 도입하고, 치료법과 치료법의 과학적 발견과 혁신을 가속화하는 것을 목표로 하고 있습니다. 그러나 이 시장은 제조 규모 확대에 따른 기술적 한계와 같은 큰 문제에 직면해 있으며, 이를 극복하기 위해서는 전문 장비와 인프라가 필요합니다.

줄기세포 제조 시장 동향 :

줄기세포 연구 및 재생의료에 대한 투자 증가

세계 줄기세포 제조 시장은 줄기세포 연구 및 재생의료에 대한 막대한 투자로 인해 급성장하고 있습니다. 정부 및 민간 기관들은 헬스케어에 혁명을 가져올 수 있는 잠재력을 인식하고 이 분야에 자원을 투입하고 있습니다. 이러한 원동력은 신경 퇴행성 질환이나 척수 손상 등 그동안 치료가 불가능하다고 여겨졌던 질병에 대한 줄기세포 치료의 유망한 전망에 있습니다. 예를 들어 2023년 8월 New England Journal of Medicine에 게재된 논문은 겸상적혈구증(SCD) 치료에서 줄기세포 유전자 치료의 가능성을 보여주었습니다. 이러한 투자는 최첨단 연구, 첨단 제조 기술 개발, 임상시험 확대를 지원하고 있습니다. 예를 들어 2021년 9월 LifeCell International Pvt. Ltd는 OrbiMed Asia Partners IV로부터 225억 루피(2,720만 달러)를 투자받아 회사의 기술 전문성과 광범위한 네트워크를 더욱 활용하여 불임 치료 및 세포 기반 치료제를 포함한 불임 치료 및 세포 기반 치료제 등 인접한 새로운 카테고리로 진출했습니다. 또한 2023년 11월에는 재조합 단백질 및 필수 시약 전문 기업인 미국 ACROBiosystems Inc.가 줄기세포 발생과 분화에 중요한 델타 유사 리간드 4(DLL4)의 가용성 형태인 GM급 DLL4 단백질을 출시했습니다.

만성질환 증가와 혁신적 치료에 대한 수요 증가

세계 줄기세포 제조 시장을 촉진하는 또 다른 중요한 원동력은 만성질환의 유병률 증가입니다. 당뇨병, 심장병, 자가면역질환 등의 치료가 증가 추세에 있으며, 참신하고 효과적인 치료법이 요구되고 있습니다. 줄기세포 치료는 손상된 조직과 장기를 재생시킴으로써 이러한 질병에 대처하는 데 있으며, 매우 유망한 치료법입니다. 예를 들어 2021년 3월 버텍스 파마슈티컬스(Vertex Pharmaceuticals)는 FDA로부터 1형 당뇨병 환자를 위한 인간 줄기세포 유래 치료제 VX-880에 대한 패스트트랙 지정을 받았습니다. 또한 미국 식품의약국(FDA)이 2022년 12월에 발표한 자료에 따르면 미국에는 3,000만 명 이상이 앓고 있는 7,000개 이상의 희귀질환이 존재합니다. 만성질환의 발병률은 나이가 들어감에 따라 증가하는데, 줄기세포 제조는 이러한 질병을 퇴치하는 데 유망합니다. 예를 들어 2021년 10월에 발표된 세계보건기구(WHO)의 팩트 시트에 따르면 2030년까지 전 세계 65세 이상 노인이 14억 명에 달할 것이며, 2050년에는 22억 명으로 두 배로 늘어날 것으로 예상됩니다.

생명공학 및 세포배양 기술의 발전

생명공학 및 세포배양 기술의 발전은 줄기세포 제조 분야에 혁명을 일으키고 있습니다. 이러한 원동력은 줄기세포 제조의 효율성과 확장성을 높이는 데 매우 중요하며, 3D 세포배양 시스템 및 바이오리액터와 같은 세포배양 기술의 획기적인 발전은 고품질의 줄기세포를 대량으로 배양할 수 있게 해줍니다. 또한 CRISPR-Cas9와 같은 유전자 편집 기술의 혁신은 줄기세포의 특성을 정확하게 제어하여 치료의 가능성을 더욱 넓혀줄 수 있습니다. 이러한 발전은 제조 공정을 간소화할 뿐만 아니라 줄기세포를 이용한 치료법의 안전성과 품질을 보장하여 의료진과 환자들에게 신뢰감을 주고 있습니다. 예를 들어 2021년 9월 미국의 줄기세포 제조 전문 바이오 기업 Cellino는 AI, 머신러닝, 레이저 및 기타 하드웨어와 소프트웨어를 통합한 시스템을 통해 수율을 개선하고 제조 비용을 절감하는 방법을 발표했습니다.

목차

제1장 서문

제2장 조사 범위와 조사 방법

• 조사의 목적
• 이해관계자
• 데이터 소스
  • 1차 정보
  • 2차 정보
• 시장 추정
  • 보텀업 어프로치
  • 톱다운 어프로치
• 조사 방법

제3장 개요

제4장 서론

• 개요
• 주요 업계 동향

제5장 세계의 줄기세포 제조 시장

• 시장 개요
• 시장 실적
• COVID-19의 영향
• 시장 예측

제6장 시장 내역 : 제품별

• 소모품
  • 주요 부문
    • 배지
    • 기타
• 기기
  • 주요 부문
    • 바이오리액터·인큐베이터
    • 세포 선별기
    • 기타
• 줄기세포주
  • 주요 부문
    • 조혈모세포(HSC)
    • 중간엽줄기세포(MSC)
    • 유도만능줄기세포(iPSC)
    • 배아줄기세포(ESC)
    • 신경줄기세포(NSC)
    • 다능성 성체 전구 줄기세포

제7장 시장 내역 : 용도별

• 조사 애플리케이션
  • 주요 부문
    • 생명과학 연구
    • 의약품 발견과 개발
• 임상 응용
  • 주요 부문
    • 동종 줄기세포 요법
    • 자가 줄기세포 요법
• 세포·조직은행 애플리케이션

제8장 시장 내역 : 최종사용자별

• 제약·바이오테크놀러지 기업
• 학술기관, 연구기관, 위탁 조사기관
• 병원·외과 센터
• 세포·조직은행
• 기타

제9장 시장 내역 : 지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 인도네시아
  • 기타
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 러시아
  • 기타
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 시장 내역 : 국가별

제10장 SWOT 분석

• 개요
• 강점
• 약점
• 기회
• 위협

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

• 개요
• 바이어의 교섭력
• 공급 기업의 교섭력
• 경쟁의 정도
• 신규 진출업체의 위협
• 대체품의 위협

제13장 가격 분석

제14장 경쟁 구도

• 시장 구조
• 주요 기업
• 주요 기업의 개요
  • Anterogen Co. Ltd.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Corporation
  • Corning Incorporated
  • FUJIFILM Holdings Corporation
  • Lonza Group AG
  • Merck KGaA
  • Sartorius AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

KSA

영문 목차

영문목차

The global stem cell manufacturing market size reached USD 14.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.8 Billion by 2033, exhibiting a growth rate (CAGR) of 6.8% during 2025-2033. Increasing investments in stem cell research, rising chronic disease prevalence, advancements in biotechnology, collaborations between academia and industry, stringent regulations, and expanding awareness of stem cell therapies are stimulating the market growth.

Stem Cell Manufacturing Market Analysis:

• Major Market Drivers: Growing venture capital investment in stem cell research, supported by favorable government initiatives are majorly driving the stem cell manufacturing market. This, in turn, reflects the increasing recognition of stem cell's potential in advancing healthcare and regenerative medicine.
• Key Market Trends: Some of the key trends in the stem cell manufacturing market include rising expenditure on stem cell research and regenerative medicine, automation of processes, increasing collaborations among industry players, and rapid advancements in bioreactor technology.
• Geographical Trends: North America is leading the stem cell manufacturing market due to several factors, including the presence of leading biotechnology and pharmaceutical companies, a supportive regulatory framework towards clinical trials and commercialization of stem cell manufacturing, robust research and development (R&D) infrastructure, and the rising demand for regenerative medicine therapies in the region.
• Competitive Landscape: Some of the major market players in the stem cell manufacturing industry include Anterogen Co. Ltd., Becton Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Corning Incorporated, FUJIFILM Holdings Corporation, Lonza Group AG, Merck KGaA, Sartorius AG, Takara Bio Inc., and Thermo Fisher Scientific Inc., among many others.
• Challenges and Opportunities: Government initiatives to boost the biotechnology and biopharmaceutical industries represent a significant opportunity for the market. Initiatives, such as grants, tax incentives, and subsidies, aim to promote R&D, attract investments, adopt advanced technologies, and accelerate scientific discoveries and innovations in therapies and treatments. However, the market also faces a significant challenge like technical limitations associated with manufacturing scale-up, which will require companies specialized equipment and infrastructure to overcome.

Stem Cell Manufacturing Market Trends:

Increasing Investments in Stem Cell Research and Regenerative Medicine

The global stem cell manufacturing market is experiencing a significant upsurge due to the substantial investments pouring into stem cell research and regenerative medicine. Governments and private organizations are channeling resources toward these fields, recognizing their potential to revolutionize healthcare. This driver is fueled by the promising prospects of stem cell therapies in addressing previously untreatable conditions, such as neurodegenerative diseases and spinal cord injuries. For instance, an article published in the New England Journal of Medicine in August 2023 revealed the anticipated potential of stem cell gene therapy in treating Sickle Cell Disease (SCD). These investments support cutting-edge research, the development of advanced manufacturing techniques, and the expansion of clinical trials. For example, in September 2021, LifeCell International Pvt. Ltd received an investment of INR 225 crore (USD 27.2 million) from OrbiMed Asia Partners IV to further leverage its technological expertise and wide network to foray into adjacent new categories like fertility health and cell-based therapeutics. Moreover, in November 2023, ACROBiosystems Inc., a US-based company specializing in recombinant proteins and essential reagents, launched GM-grade DLL4 protein, a soluble form of Delta-like Ligand 4 (DLL4), crucial in stem cell development and differentiation.

Rising Prevalence of Chronic Diseases and the Demand for Innovative Treatments

Another vital driver propelling the global stem cell manufacturing market is the escalating prevalence of chronic diseases. Conditions like diabetes, heart disease, and autoimmune disorders are on the rise, necessitating novel and effective treatments. Stem cell therapies hold immense promise in addressing these ailments by regenerating damaged tissues and organs. For instance, in March 2021, Vertex Pharmaceuticals received FDA grant as a fast track designation to VX-880, a human stem-cell derived therapy for patients with Type-1 diabetes. Moreover, as per the December 2022 data provided by the US Food and Drug Administration (FDA), there are over 7,000 rare diseases that affect more than 30 million people in the United States. The prevalence of chronic diseases rises with age, and stem cell manufacturing exhibits promise in combating these conditions. For example, a World Health Organization factsheet from October 2021 projects that globally there will be 1.4 billion people over the age of 65 by 2030 and this number is expected to double at 2.2 billion by 2050.

Advancements in Biotechnology and Cell Culture Techniques

Advancements in biotechnology and cell culture techniques are revolutionizing the field of stem cell manufacturing. This driver is pivotal in enhancing the efficiency and scalability of stem cell production. Breakthroughs in cell culture technology, such as 3D cell culture systems and bioreactors, enable the cultivation of high-quality stem cells in larger quantities. Additionally, innovations in genetic editing techniques, like CRISPR-Cas9, offer precise control over stem cell characteristics, further expanding their therapeutic potential. These advancements not only streamline the manufacturing process but also ensure the safety and quality of stem cell-based therapies, instilling confidence among healthcare professionals and patients alike. For instance, in September 2021, Cellino, a US-based biotech company with specialization in stem cell manufacturing, presented how its system integrates AI, machine learning, and lasers, along with other hardware and software, to enhance yields and reduce production costs.

Stem Cell Manufacturing Market Segmentation:

Breakup by Product:

• Consumables
  • Culture Media
  • Others
• Instruments
  • Bioreactors and Incubators
  • Cell Sorters
  • Others
• Stem Cell Lines
  • Hematopoietic Stem Cells (HSC)
  • Mesenchymal Stem Cells (MSC)
  • Induced Pluripotent Stem Cells (iPSC)
  • Embryonic Stem Cells (ESC)
  • Neural Stem Cells (NSC)
  • Multipotent Adult Progenitor Stem Cells

Consumables dominate the market

The consumables segment within the stem cell manufacturing market is experiencing robust growth due to the increasing adoption of stem cell-based research and therapies, necessitating a constant supply of consumables, including cell culture media, reagents, and growth factors. As research in this field expands, so does the demand for these essential materials. Moreover, the growing number of stem cell clinical trials and applications in regenerative medicine fuels the consumption of consumables. Clinical research and therapy development require a consistent and reliable source of high-quality consumables to ensure the safety and efficacy of stem cell-based treatments. In line with this, technological advancements in the production of consumables are driving growth.

Breakup by Application:

• Research Applications
  • Life Science Research
  • Drug Discovery and Development
• Clinical Application
  • Allogenic Stem Cell Therapy
  • Autologous Stem Cell Therapy
• Cell and Tissue Banking Applications

Research applications dominate the market

The growth of the research applications segment within the stem cell manufacturing market is underpinned by the relentless pursuit of scientific knowledge and breakthrough discoveries in stem cell biology. Stem cells serve as essential tools for investigating various biological processes, disease mechanisms, and potential therapeutic avenues. Researchers across diverse fields, including regenerative medicine, developmental biology, and drug development, rely on stem cells to advance their studies. Moreover, the increasing funding and grants allocated to stem cell research bolster this segment's growth. Governments, private institutions, and non-profit organizations recognize the transformative potential of stem cell research and provide financial support to drive innovation. Additionally, technological advancements in stem cell culture techniques, genetic editing, and cell characterization tools enhance the efficiency and accuracy of research applications. These advancements enable researchers to work with a broader range of stem cell types and manipulate them with precision, further expanding the scope of research possibilities. For instance, in May 2023, Sernova announced research collaboration with AstraZeneca to evaluate novel potential therapeutic cell applications.

Breakup by End User:

• Pharmaceutical & Biotechnology Companies
• Academic Institutes, Research Laboratories and Contract Research Organizations
• Hospitals and Surgical Centers
• Cell and Tissue banks
• Others

Pharmaceutical & biotechnology companies dominate the market

The growth of pharmaceutical and biotechnology companies is propelled by the continuous expansion of the global population and the aging demographic trends. With an aging population, the demand for healthcare services, medications, and innovative therapies rises, providing a substantial market for pharmaceutical and biotechnology companies to cater to. Moreover, the increasing prevalence of chronic diseases, including cardiovascular disorders, cancer, and diabetes, necessitates ongoing research and the development of new pharmaceutical solutions. These companies play a pivotal role in creating advanced drugs and therapies to combat these health challenges. Furthermore, advancements in biotechnology, including gene therapy, precision medicine, and biopharmaceuticals, are shaping the industry.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest stem cell manufacturing market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The North American region is experiencing robust growth in the stem cell manufacturing market, propelled by the substantial government funding and private investments in stem cell research and regenerative medicine. These financial commitments support cutting-edge research, clinical trials, and the development of advanced manufacturing techniques. Moreover, the prevalence of chronic diseases, such as diabetes, heart disease, and neurodegenerative disorders, is on the rise in North America. Stem cell therapies offer innovative solutions to address these conditions, fueling demand for their production. In line with this, the region boasts a highly developed biotechnology sector, leading to significant advancements in cell culture techniques and bioprocessing technologies. This ensures efficient and scalable stem cell production, strengthening the industry's foothold in North America. Furthermore, regulatory frameworks in North America provide a conducive environment for stem cell research and clinical trials, fostering growth and innovation. Collaborative efforts between academic institutions and industry players, along with growing public awareness of the potential of stem cell-based treatments, are additional drivers.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the Stem Cell Manufacturing industry include Anterogen Co. Ltd., Becton Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Corning Incorporated, FUJIFILM Holdings Corporation, Lonza Group AG, Merck KGaA, Sartorius AG, Takara Bio Inc., and Thermo Fisher Scientific Inc., among many others.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

• The competitive landscape within the global stem cell manufacturing market is characterized by a dynamic interplay of numerous players, each vying to establish their prominence and contribute to the industry's growth. These entities span a spectrum of organizations, including research institutions, biotechnology companies, pharmaceutical giants, and contract manufacturing organizations. Their diverse backgrounds and resources contribute to a multifaceted ecosystem that fosters innovation and advancements in stem cell manufacturing. Key competitive strategies encompass research and development efforts to enhance manufacturing processes, scale up production, and improve the quality and safety of stem cell-based therapies. Additionally, partnerships and collaborations between these players are common, facilitating knowledge sharing and the development of cutting-edge technologies. For instance, in June 2021, Catalent, in a strategic move, acquired RheinCell Therapeutics Gmbh for an undisclosed amount to expand the creation of advanced cell treatments, thereby enhancing Catalent's capacity for large-scale production. Regulatory compliance and adherence to ethical standards are pivotal in maintaining credibility within the market. Moreover, market participants often engage in marketing and educational initiatives to increase awareness of stem cell therapies among healthcare professionals and the public, further expanding their reach.

Key Questions Answered in This Report

• 1.What was the size of the global stem cell manufacturing market in 2024?
• 2.What is the expected growth rate of the global stem cell manufacturing market during 2025-2033?
• 3.What are the key factors driving the global stem cell manufacturing market?
• 4.What has been the impact of COVID-19 on the global stem cell manufacturing market?
• 5.What is the breakup of the global stem cell manufacturing market based on product?
• 6.What is the breakup of the global stem cell manufacturing market based on the application?
• 7.What is the breakup of the global stem cell manufacturing market based on the end user?
• 8.What are the key regions in the global stem cell manufacturing market?
• 9.Who are the key players/companies in the global stem cell manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Stem Cell Manufacturing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Consumables
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Culture Media
    • 6.1.2.2 Others
  • 6.1.3 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Bioreactors and Incubators
    • 6.2.2.2 Cell Sorters
    • 6.2.2.3 Others
  • 6.2.3 Market Forecast
• 6.3 Stem Cell Lines
  • 6.3.1 Market Trends
  • 6.3.2 Key Segments
    • 6.3.2.1 Hematopoietic Stem Cells (HSC)
    • 6.3.2.2 Mesenchymal Stem Cells (MSC)
    • 6.3.2.3 Induced Pluripotent Stem Cells (iPSC)
    • 6.3.2.4 Embryonic Stem Cells (ESC)
    • 6.3.2.5 Neural Stem Cells (NSC)
    • 6.3.2.6 Multipotent Adult Progenitor Stem Cells
  • 6.3.3 Market Forecast

7 Market Breakup by Application

• 7.1 Research Applications
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Life Science Research
    • 7.1.2.2 Drug Discovery and Development
  • 7.1.3 Market Forecast
• 7.2 Clinical Application
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Allogenic Stem Cell Therapy
    • 7.2.2.2 Autologous Stem Cell Therapy
  • 7.2.3 Market Forecast
• 7.3 Cell and Tissue Banking Applications
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Pharmaceutical & Biotechnology Companies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Academic Institutes, Research Laboratories and Contract Research Organizations
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Hospitals and Surgical Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Cell and Tissue banks
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Anterogen Co. Ltd.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Becton Dickinson and Company
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Bio-Rad Laboratories Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Bio-Techne Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Corning Incorporated
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 FUJIFILM Holdings Corporation
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Lonza Group AG
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Merck KGaA
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Sartorius AG
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Takara Bio Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
  • 14.3.11 Thermo Fisher Scientific Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis

관련자료